Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Follow up complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1 randomized, double-blind, placebo controlled clinical trial to evaluate the safety and immunogenicity of an HIV-1 vaccine regimen of DNA prime with 3 different HIV-1 envelope inserts (Nat-B env, CON-S env, and Mosaic env) with MVA-CMDR boost in healthy, HIV-1 uninfected adults
Description
HVTN 106 is a Phase I clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of DNA Nat-B env, DNA CON-S env, DNA Mosaic env, and MVA-CMDR.
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.